TABLE 1.
Patient Demographics and Clinical Characteristics
| Characteristic | Trastuzumab protein dose
|
All patients | |
|---|---|---|---|
| 5 mg | 50 mg | ||
| No. of patients | 2 | 6 | 8 |
|
| |||
| Age (years) | |||
| median | 60 | 54 | 56 |
| range | 44-75 | 39-69 | 39-75 |
|
| |||
| No. of patients | |||
| Prior anti-HER2 therapy | |||
| none | 1 | 1 | |
| adjuvant trastuzumab | 1 | 2 | 3 (14, 18, 18)† |
| trastuzumab for metastasis | 1 | 3 | 4 (4, 6, 14, 18)† |
|
| |||
| Hormone receptor and HER2 status of recurrent disease | |||
| ER and/or PR positive | 1 | 3 | 4 |
| ER and PR negative | 1 | 3 | 4 |
| HER2 | |||
| IHC3+ | 2 | 5 | 7 |
| IHC2+/FISH positive | 1 | 1 | |
|
| |||
| Sites of metastatic disease | |||
| bone | 2 | 4 | 6 |
| lymph nodes | 2 | 5 | 7 |
| liver | 2 | 2 | 4 |
| lung | 1 | 1 | 2 |
| pleural effusion | 1 | 1 | |
| breast | 2 | 2 | |
†
months since last anti-HER2 therapy administration
ER = estrogen receptor; PR = progesterone receptor;
IHC = immunohistochemistry; FISH = fluorescence in situ hybridization